15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Amylyx Pharmaceuticals Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $19.00 to $57.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $36.50 sits 8% above the current $33.91. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.37 next quarter toward $-1.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Amylyx Pharmaceuticals Inc.
As of Sep, 7 of 7 firms rate AMLX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AMLX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.37
Range $-0.41 – $-0.26 · 8 analysts · +22% YoY
Next period, 8 analysts expect Amylyx Pharmaceuticals Inc to earn $-0.37 a share (range $-0.41 – $-0.26), versus $-0.30 a year earlier. Full-year consensus is $-1.50, growing to $-1.15 the year after.
REVENUE · NEXT QUARTER
$-37.8K
Range $-416.0K – $0 · 8 analysts · +0% YoY
Revenue is expected to reach $-37.8K (range $-416.0K – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $28.2M next year.
Top analysts covering Amylyx Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AMLX.
#1
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$55.00+62.2% to target
Overall win rate
46%
+ Follow
#2
Joel Beatty
Baird · Rank #80
Buy
$52.00+53.3% to target
Overall win rate
48%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #125
Buy
$39.00+15.0% to target
Overall win rate
46%
+ Follow
#4
Graig Suvannavejh
Mizuho
Buy
$42.00+23.9% to target
Coverage
—
+ Follow
#5
Seamus Fernandez
Guggenheim
Buy
$57.00+68.1% to target
Coverage
—
+ Follow
AMLX stock forecast FAQ
What is AMLX's average 12-month price target?+
The 8 analysts with a live target average $36.50 for Amylyx Pharmaceuticals Inc over the next 12 months, ranging from a $57.00 high to a $19.00 low.
Is AMLX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AMLX?+
The Street-high target is $57.00 (Guggenheim), and the Street-low is $19.00 (B of A Securities). The average of all 8 active targets is $36.50.
How many Wall Street analysts cover AMLX?+
8 analysts have an active rating on Amylyx Pharmaceuticals Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering AMLX?+
Among analysts who currently cover AMLX, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $55.00 target.
What is Amylyx Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.37 per share (range $-0.41 – $-0.26) across 8 analysts. Full-year EPS is projected at $-1.50, rising to $-1.15 the following year.
How much revenue is Amylyx Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $-37.8K (range $-416.0K – $0). Full-year revenue is projected at $0, growing to $28.2M next year.
Have analysts been upgrading or downgrading AMLX lately?+
As of Sep, 7 of 7 firms rate AMLX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AMLX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
